Iadademstat is under clinical development by Oryzon Genomics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Iadademstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Iadademstat (ORY-1001) is under development for the treatment of small cell lung cancer, newly diagnosed, relapsed and refractory acute myeloid leukemia (AML) and neuroendocrine carcinoma. The drug candidate is administered orally. It is a new molecular entity (NME). The drug candidate targets lysine specific demethylase-1 (LSD1, aka KDM1). It is developed based on epigenetic platform. It was also under development for solid tumors like prostate cancer and breast cancer.
Oryzon Genomics overview
Oryzon Genomics (Oryzon) is a clinical-stage biopharmaceutical company that offers discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company provides epigenetics, a regulatory system that controls gene expression without affecting the makeup of the genes themselves and provides regulation of gene transcription that has emerged as a key biological determinant of protein production and cellular differentiation. Its clinical-stage product include ORY-1001, an oncology product for treating acute leukemia disease; ORY-2001 for treating Alzheimer disease, Parkinson disease and others; and ORY-3001 for treating other indications of cancer. Oryzon provides therapeutic programs and collaborative research services. The company serves patients with cancers or neurodegenerative disorders. It operates office in Spain and the US. Oryzon is headquartered in Cornella de Llobregat, Barcelona, Spain.
For a complete picture of Iadademstat’s drug-specific PTSR and LoA scores, buy the report here.